Serum survivin level in prolactinoma

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 88-129-Acromegaly & Prolactinoma
Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-128
Fatma Dilek Dellal*1, Mutlu Niyazoglu2, Esranur Ademoglu3, Zehra Candan3, Suheyla Gorar4, Handan Bekdemir5, Ziynet alphan Uc6, Cavit Culha7 and Yalcin Aral3
1Agri Government Hospital, Agri, Turkey, 2Istanbul Training and Research Hospital, 3Ankara Training and Research Hospital, Ankara, Turkey, 4Antalya Training and Research Hospital, Antalya, Turkey, 5Ankara Training and Research Hospital, Turkey, 6Usak Government Hospital, 7Ankara Training and Research Hospital
Background:Survivin is a member of the family of inhibitors of apoptosis proteins. Its expression is observed in many tumors (1). Pituitary tumors develop when the balance is disturbed between cell proliferation and cell death. Prolactinoma is the most common adult pituitary adenoma. Survivin is undetectable in most adult tissues but its abundant expression shown in most human tumoral cells. Survivin expression has shown in prolactinoma tissue before but no study exists showing serum survivin level (2-5).

Aim:The aim of the present study is to investigate plasma survivin levels in patients diagnosed with prolactinoma and demonstrate if it could be used a marker in diagnosis.

Materials and Methods: Prolactinoma patients were chosen among patients whose initial serum prolactin levels were greater than 250 ng/mL together with the presence of pituitary MRI showing adenoma. Other functional pituitary tumors were excluded by dynamic hormone tests in all patients. The group of patients consisted of 50 women, aged from 17 to 51 years. As a control group, 42 healthy women, aged from 22 to 45 years were included. Twenty patients were microprolactinoma, while five patients were macroprolactinoma. All patients received dopamine agonist therapy. Serum survivin levels were measured in the both groups.

Results: Survivin levels were significantly higher in patients with prolactinoma compared to controls [19 (10-39) pg/mL, 16 (8 -22), p = 0.042]. There was no difference between microadenoma and macroadenoma patients in survivin levels [17.5 (range, 10-38) pg/mL, 19 (range, 16-22) pg/mL; p = 0.879). Mean sizes of microadenomas and macroadenomas were 5 (range, 2-7) mm and 12 (range, 11-26) mm.

Conclusions: Higher survivin levels might be a molecular marker predicting the presence of prolactinoma. Large-scale research is needed to clarify its role in diagnosis of prolactinoma patients.

1. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012;14(2):120-8 2. Wasko R, Waligorska-Stachura J, Jankowska A, Warchol JB, Liebert W, Sowinski J. Coexpression of survivin and PCNA in pituitary tumors and normal pituitary. Neuro Endocrinol Lett 2009;30(4):477-81. 3. Zhang YC, Gao J, Xin T, Ehrlich SM, Fields JZ, Boman BM. Expression of survivin in invasive pituitary adenoma. Saudi Med J 2008;29(11):1589-92. 4. Jankowska A, Wasko R, Waligorska-Stachura J, Andrusiewicz M, Jaskula M, Liebert W, et al. Survivin products in pituitary tumors. Neuro Endocrinol Lett 2008;29(6):1033-7. 5. Wasko R, Waligorska-Stachura J, Jankowska A, Warchol JB, Liebert W, Sowinski J. Coexpression of survivin and PCNA in pituitary tumors and normal pituitary. Neuro Endocrinol Lett 2009;30(4):477-81. 6. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(2):273-88.

Nothing to Disclose: FDD, MN, EA, ZC, SG, HB, ZA, CC, YA

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm